Conditions: HIV-Associated Lipodystrophy Syndrome
Keywords: HIV infections
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 219
Healthy volunteers: no

Brief summary:
The purpose of this clinical research study is to learn if human immunodeficiency virus (HIV)-infected subjects with abdominal fat accumulation on their highly active antiretroviral treatment (HAART) regimen have better changes in fat distribution after switching to atazanavir-ritonavir than those remaining on their current protease inhibitor boosted HAART regimen.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs) intervention 2: continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
Intervention descriptions: intervention 1: Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks intervention 2: Protease inhibitor \[PI\] combination + 2 NRTIs

Protocol document: